Search clinical trials for: AK0529

Total 32 results

Ark Biosciences Inc.

Terminated

A Study of AK0529 in Infants Hospitalized With RSV

Respiratory Syncytial Virus Infections

Australia
Ark Biosciences Inc.

Completed

Safety, Tolerability and PK Study of AK0529 in Healthy Human

Respiratory Syncytial Virus Infections

Australia
Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd.

Completed

A Study of AK0529 in Chinese Infants Hospitalized With RSV (AIRFLO)

Respiratory Syncytial Virus Infections

China
Shanghai Ark Biopharmaceutical Co., Ltd.
Ark Biosciences Pty Ltd.

Completed

Viral Inhibition in Children for Treatment of RSV (VICTOR)

RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

Australia, Hong Kong, Israel, Lebanon, Malaysia, Poland, Taiwan, Turkey
Ark Biosciences Inc.

Completed

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects

Healthy Subjects

United States
Ark Biosciences Inc.

Completed

A Study of AK0529 to Evaluate Pharmacokinetics and Safety in Chinese Healthy Volunteers

Healthy

China
Ark Biosciences Inc.

Unknown

Anti-RSV Study in Chinese Patients (ASCENT) (ASCENT)

Respiratory Syncytial Virus Infections

China
Ark Biosciences Inc.

Completed

A Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of AK0529

Healthy

United Kingdom
Merck Sharp & Dohme LLC

Completed

Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005)

Post-Menopausal Osteoporosis
Merck Sharp & Dohme LLC

Completed

MK0524 Seasonal Allergic Rhinitis Study (0524-005)(COMPLETED)

Seasonal Allergies
Allakos Inc.

Active, not recruiting

A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria (MAVERICK)

Chronic Spontaneous Urticaria

United States, Germany, Poland
Allakos Inc.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002

Indolent Systemic Mastocytosis

Germany
Allakos Inc.

Completed

Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AK002 in Healthy Participants

Healthy

Australia
Merck Sharp & Dohme LLC

Completed

MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011)

Prostatic Neoplasms
Allakos Inc.

Completed

A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria (CURSIG)

Chronic Urticaria

United States, Germany
Allakos Inc.

Completed

An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis

Eosinophilic Gastritis | Eosinophilic Gastroenteritis | Eosinophilic Duodenitis

United States
Allakos Inc.

Active, not recruiting

A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis (ATLAS)

Atopic Dermatitis

United States, Germany
Allakos Inc.

Completed

A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) (ENIGMA 2)

Eosinophilic Gastritis | Eosinophilic Duodenitis

United States
Akeso

Recruiting

A Study of AK129 in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors(Stage IA-IB)

China
Allakos Inc.

Completed

A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis (ENIGMA)

Eosinophilic Gastritis | Eosinophilic Gastroenteritis

United States
Allakos Inc.

Completed

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis (EoDyssey)

Eosinophilic Gastroenteritis | Eosinophilic Duodenitis

United States
Allakos Inc.

Withdrawn

A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA-SC)

Eosinophilic Gastritis | Eosinophilic Duodenitis

United States
Allakos Inc.

Completed

An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

Eosinophilic Gastritis | Eosinophilic Duodenitis

United States
Allakos Inc.

Completed

A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis (KRONOS)

Vernal Keratoconjunctivitis | Perennial Allergic Conjunctivitis | Atopic Keratoconjunctivitis

United States
Allakos Inc.

Completed

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis (KRYPTOS)

Eosinophilic Esophagitis

United States, Australia, Netherlands
Allakos Inc.

Completed

A Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneous Lirentelimab (AK002) in Adult Healthy Volunteers

Study Conducted in Healthy Volunteers

United States
AronPharma Sp. z o. o.

Recruiting

The Efficacy of AP029 Mix in Patients With Impaired Carbohydrate Metabolism

PreDiabetes | Diabetes in Adolescence

Poland
Pharming Technologies B.V.

Completed

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Hereditary Angioedema | Angioneurotic Edema

Netherlands
Asahi Kasei Pharma Corporation

Completed

Clinical Study of AK159 in Healthy Postmenopausal Women

Osteoporosis

Japan
Asahi Kasei Pharma Corporation

Completed

A Phase I Study of AK159 in Healthy Postmenopausal Women

Osteoporosis

Japan
Merck Sharp & Dohme LLC

Completed

MK0524 Asthma POC Study (0524-008)(COMPLETED)

Asthma
Sublimity Therapeutics Holdco Limited
Dr. Falk Pharma GmbH

Terminated

A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis

Colitis, Ulcerative

United States, United Kingdom, Serbia, Canada, Russian Federation, Poland, Israel, Romania, Ireland, Spain, Hungary, Ukraine, Belarus, Italy, Bulgaria, France, Germany

Search clinical trials for: AK0529

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations